Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8052867 | 0.87 | TNFRSF1A (0.58) | TNFRSF1AHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8063139 | 0.85 | TNFRSF1A (0.53) | TNFRSF1AHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7191864 | 0.85 | MAOB (0.53) | TNFRSF1AHPGDNPC1RAB9APDE4A | |
| SCHEMBL7191857 | 0.85 | MAOB (0.53) | TNFRSF1AHPGDNPC1RAB9APDE4A | |
| SCHEMBL8064254 | 0.84 | TNFRSF1A (0.55) | TNFRSF1AHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8064252 | 0.84 | TNFRSF1A (0.55) | TNFRSF1AHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8066764 | 0.83 | TNFRSF1A (0.54) | TNFRSF1AHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8063011 | 0.82 | TNFRSF1A (0.52) | TNFRSF1AHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25301594 | 0.81 | APP (0.70) | TNFRSF1AHPGDNPC1RAB9APDE4A | |
| SCHEMBL8069081 | 0.81 | TNFRSF1A (0.52) | TNFRSF1AHPGDNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | JAPAN ROYAL JELLEY CO., LTD. (JP) | 2011-11-24 | — | — | US | claimed |
| EP-2311472-A1 | COGNITIVE DISORDER-AMELIORATING AGENT | Japan Royal Jelly Co., Ltd. (JP) | 2011-04-20 | — | — | EP | claimed |
| EP-2311472-B1 | COGNITIVE DISORDER-AMELIORATING AGENT | JAPAN ROYAL JELLY CO LTD (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20130129832-A1 | COGNITIVE IMPAIRMENT AMELIORANT | TOHOKU UNIVERSITY (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | JAPAN ROYAL JELLEY CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2311472-A1 | COGNITIVE DISORDER-AMELIORATING AGENT | Japan Royal Jelly Co., Ltd. (JP) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130129832-A1 | COGNITIVE IMPAIRMENT AMELIORANT | CHAT, ACHE, PSEN1 | TNFRSF1A 4803/4885HPGD 1000/4885NPC1 896/4885 |
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | CHAT, ACHE, PSEN1 | TNFRSF1A 4803/4885HPGD 1000/4885NPC1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.